Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure

Heart

Volumn 82, Issue 5, 1999, Pages 589-593

  Macdonald, P S ^a   Keogh, A M ^a   Aboyoun, C ^a   Lund, M ^a   Amor, R ^a   McCaffrey, D ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

Amiodarone; Carvedilol; Heart failure

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; BRADYCARDIA; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPOTENSION; LETHARGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0032743258     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.82.5.589     Document Type: Article

References (40)

1. 1 Doughty R, Whalley G, Gamble G, et al and the Australia and New Zealand Heart Failure Collaborative Research Group. Left ventricular remodelling with carvedilol in patients with congestive heart failure due to ischaemic heart disease. J Am Coll Cardiol 1997;29:1060-6.
2. 2 Metra M, Nardi M, Giubbini R, et al. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-87.
3. 3 Olsen S, Gilbert E, Renlund D, et al. Carvedilol improves left ventrieular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-31.
4. 4 Bristow M, Gilbert E, Abraham W, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:690-7.
5. 5 Packer M, Bristow M, Cohn J, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
6. 6 Colucci W, Packer M, Bristow M, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-6.
7. 7 Australia and New Zealand Heart Failure Collaborative Research Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
8. 8 Hamer AW, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial [see comments]. J Am Coll Cardiol 1989;14:1768-74.
9. 9 Mahmarian JJ, Smart FW, Moye LA, et al. Exploring the minimal dose of amiodarone with antiarrhythmic and hemodynamic activity. Am J Cardiol 1994;74:681-6.
10. 10 Massie BM, Fisher SG, Deedwania PC, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure: CHF-STAT investigators. Circulation 1996;93:2128-34.
11. 11 Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure: grupo de estudio de la sobrevida en la insuficiencia cardiaca en Argentina (GESICA) [see comments]. Lancet 1994;344:493-8.
12. 12 Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Lancet 1997;350:1417-24.
13. 13 Singh BN, Venkatesh N, Nademanee K, et al. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989;31:249-80.
14. 14 Freedman MD, Somberg JC, Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 1991;31:1061-9.
15. 15 Drvota V, Haggblad J, Blange I, et al. The effect of amiodarone on the beta-adrenergic receptor is due to a downregulation of receptor protein and not to a receptor-ligand interaction. Biochem Biophys Res Commun 1999;255:515-20.
16. 16 Haikerwal D, Dart AM, Little PJ, et al. Identification of a novel, inhibitory action of amiodarone on vesicular monoamine transport. J Pharmacol Exp Ther 1999;288: 834-7.
17. 17 Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol 1995;26;1417-23.
18. 18 Teichholz L, Kreulen T, Herman M, et al. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence and absence of asynergy. Am J Cardiol 1976;37:7-11.
19. 19 Krum H, Shusterman N, MacMahon S, et al. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy: Australia and New Zealand heart failure research collaborative group. Journal of Cardiac Failure 1998;4:281-8.
20. 20 Australia and New Zealand Heart Failure Collaborative Research Group. Effects of carvedilol, a vasodilator beta-blocker, in patients with congestive heart failure due to ischaemic heart disease. Circulation 1995;92:212-18.
21. 21 Krum H, Sackner-Bernstein J, Goldsmith R, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-506.
22. 22 Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: the V-HeFT studies. Circulation 1993;87(suppl VI):VI-102-10.
23. 23 Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure [published erratum appears in J Am Coll Cardiol 1997;30:1902]. J Am Coll Cardiol 1996,28:1458-63.
24. 23 Stevenson WG, Stevenson LW, Middlekauff HR, et al.Improving survival for patients with atrial fibrillation andadvanced heart failure [published erratum appears in J AmColl Cardiol 1997;30:1902]. J Am Coll Cardiol 1996,28: 1458-63.
25. 24 Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 1992;85(suppl I):I-50-6.
26. 25 Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998;98:946-52.
27. 26 Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998;32:695-703.
28. 27 Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998;32:197-204.
29. 28 Podrid PJ, Fogel RI, Fuchs TT. Ventricular arrhythmia in congestive heart failure. Am J Cardiol 1992;69:82G-95G; discussion 95G-96G.
30. 29 Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular tachycardia in severe heart failure: independent marker of increased mortality due to sudden death. GESICA-GEMA investigators [see comments]. Circulation 1996;94:3198-203.
31. 30 Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: survival trial of antiarrhythmic therapy in congestive heart failure [see comments]. N Engl J Med 1995;333:77-82.
32. 31 Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: Canadian amiodarone myocardial infarction arrhythmia trial investigators (CAMIAT) [published erratum appears in Lancet 1997;349:1776] [see comments]. Lancet 1997;349:675-82.
33. 31 Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial ofoutcome after myocardial infarction in patients withfrequent or repetitive ventricular prematuredepolarisations: Canadian amiodarone myocardial infarction arrhythmia trial investigators (CAMIAT) [publishederratum appears in Lancet 1997;349:1776] [sec comments]. Lancet 1997;349:675-82.
34. 32 Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: European myocardial infarct amiodarone trial investigators (EMIAT) [published errata appear in Lancet 1997;349:1180 and 1997;349:1776] [see comments]. Lancet 1997;349:667-74.
35. 32 Julian DG, Camm AJ, Frangin G, et al. Randomised trial ofeffect of amiodarone on mortality in patients withleft-ventricular dysfunction after recent myocardialinfarction: European myocardial infarct amiodarone trialinvestigators (EMIAT) [published errata appear in Lancet1997;349:1180 and 1997;349:1776] [see comments]. Lancet 1997;349:667-74.
36. 33 Packer M. The placebo effect in heart failure. Am Heart J 1990;120:1579-82.
37. 34 Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly-patients with congestive heart failure [see comments]. N Engl J Med 1995;333:1190-5.
38. 35 Smith LE, Fabbri SA, Pai R, et al. Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. Clin Cardiol 1997;20:949-54.
39. 36 Trobaugh GB, Kudenchuk PJ, Greene HL, et al. Effect of amiodarone on ventricular function as measured by gated radionuclide angiography. Am J Cardiol 1984;54:1263-6.
40. 37 Cleland JG, Dargie HJ, Findlay IN, et al. Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. Br Heart J 1987;57:436-45.